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Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Allergens (NDA) was asked to deliver an opinion on nicotinamide riboside chloride as a novel food (NF)
pursuant to Regulation (EU) 2015/2283, including an evaluation of the safety of its use in food
supplements as a source of niacin, and the bioavailability of nicotinamide from this source, in the
context of Directive 2002/46/EC. The NF, a synthetic form of nicotinamide riboside, is proposed to be
used in food supplements for the healthy adult population at levels up to 300 mg/day. The production
process, composition, specifications, batch-to-batch variability and stability of the NF do not raise
safety concerns. Animal and human data indicate that the NF contributes to the nicotinamide body
pool. There are no concerns regarding genotoxicity. Human studies do not raise safety concerns. The
proposed maximum use level corresponds to an amount of nicotinamide, which is sixfold lower than
the tolerable upper intake level (UL) set for adults, excluding pregnant and lactating women. The
margin of exposure (MoE) of 70 derived from repeated dose toxicity studies with rats and dogs is
considered sufficient for the adult population, excluding pregnant and lactating women. Regarding
these two population groups, the MoE of 76 derived from a developmental toxicity study in rats is
considered insufficient in the absence of data which could justify accepting a MoE lower than 100. The
Panel concludes that the NF is safe under the proposed conditions of use for the healthy adult
population, excluding pregnant and lactating women, and that an intake of the NF up to 230 mg/day
is safe for pregnant and lactating women. The Panel also concludes that the NF is a source from which
nicotinamide, a form of niacin, is bioavailable.
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Summary
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
Allergies (NDA) was asked to deliver an opinion on nicotinamide riboside chloride as a novel food (NF)
pursuant to Regulation (EU) 2015/2283 including an evaluation of the safety of its use in food
supplements as a source of niacin, and the bioavailability of nicotinamide, a form of niacin, from this
source, in the context of Directive 2002/46/EC. The assessment of the safety of this NF follows the
methodology set out in the EFSA Guidance on the preparation and presentation of an application for
authorisation of a novel food Regulation (EU) 2015/2283 and in the Commission Implementing
Regulation (EU) 2017/2469 and in the EFSA Guidance on safety evaluation of sources of nutrients and
bioavailability of nutrient from the sources. The assessment is based on the data supplied in the
application and the information submitted by the applicant following EFSA’s requests for supplementary
information.
The NF is obtained through chemical synthesis and contains ≥ 90% nicotinamide riboside chloride,
the remaining components being residual solvents, reaction by-products and degradation products.
Information provided on the production process, composition, specifications, batch-to-batch variability
and stability of the NF is sufficient and does not raise concerns about the safety of the NF.
The applicant proposes to market the NF as a source of niacin in food supplement capsules at
levels up to 300 mg/day. The NF is intended for use by the general healthy adult population, including
pregnant and lactating women.
Considering the outcomes of the bacterial reverse mutagenicity test, the in vivo mammalian
erythrocyte micronucleus test and the in vitro mammalian chromosome aberration test conducted with
the NF, as well as its nature, the Panel considers that there are no concerns regarding genotoxicity.
From the data on absorption, distribution, metabolism and elimination available in mice, rats, dogs
and humans, the Panel notes that the NF is likely to be absorbed mainly as nicotinamide following
hydrolysis in the gut. If a fraction of the NF were absorbed intact, it would be expected to be rapidly
metabolised to nicotinamide in the blood. Upon absorption, the NF contributes to the nicotinamide
body pool, i.e. acts as a precursor of NAD+ in cells and is primarily metabolised in the liver to
1-methylnicotinamide through methylation and subsequently to N-methyl-2-pyridone-carboxamide and
N-methyl-4-pyridone-carboxamide, following oxidation. These metabolites are then excreted in the
urine.
The Panel derives a no observed adverse effect level (NOAEL) of 300 mg/kg body weight (bw) per
day from the available repeated dose toxicity studies with rats and dogs conducted with the NF. The
Panel notes that, in the 90-day study in rats, the same effects were observed in rats which received a
dose of 1,260 mg/kg bw per day nicotinamide (equimolar to 3,000 mg/kg bw per day nicotinamide
riboside chloride) as in those which received 3,000 mg/kg bw per day nicotinamide riboside chloride.
Reproductive and developmental toxicity studies in rats were also provided, which indicate a NOAEL
for fertility and reproductive performance of 675 mg/kg bw per day in males and 1,088 mg/kg bw per
day in females and a NOAEL for maternal and embryo/fetotoxicity of 325 mg/kg bw per day. The
embryo/fetotoxicity findings are considered secondary to maternal toxicity.
The Panel considers that available human studies on the NF, which were conducted in healthy adult
subjects with dosages from 100 mg for 1 day up to 2,000 mg/day for up to 12 weeks, do not raise
safety concerns. The proposed maximum use level of 300 mg nicotinamide riboside chloride per day
corresponds to an intake of nicotinamide of 126 mg/day. This amount exceeds the population
reference intake (PRI) of 1.6 niacin equivalent (NE) mg/MJ for all population groups (in adults ranging
from 10.5 to 21.8 mg NE per day) and mean intakes from background diet (27.5–50.1 mg NE/day for
adult females and males across EU countries) (EFSA NDA Panel, 2014). However, this intake is sixfold
lower than the tolerable upper intake level (UL) for nicotinamide of 900 mg/day in adults (excluding
pregnant and lactating women).
The margin of exposure (MoE) between the proposed maximum use level of 300 mg/day (i.e.
4.3 mg/kg bw in a 70-kg adult) and the NOAEL of 300 mg/kg bw per day derived from animal data is
70. However, in the light of the human data available on nicotinamide riboside chloride and
nicotinamide, the Panel considers that this MoE is sufficient for the adult population, excluding
pregnant and lactating women.
The MoE between the proposed maximum use level of 300 mg/day (i.e. 4.3 mg/kg bw in a 70-kg
adult) and the NOAEL of 325 mg/kg bw per day for maternal and embryo/fetotoxicity is 76. In the
absence of data which could justify accepting a MoE lower than 100 for pregnant and lactating
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women, the Panel concludes that an intake of 230 mg/day of the NF is safe for these two population
groups.
The Panel concludes that the NF, nicotinamide riboside chloride, is safe under the proposed uses
and use levels, i.e. up to 300 mg/day, for the healthy adult population, excluding pregnant and
lactating women. The Panel concludes that an intake of the NF up to 230 mg/day is safe for pregnant
and lactating women.
The Panel also concludes that nicotinamide riboside chloride is a source from which nicotinamide,
which is a form of niacin, is bioavailable.
Nicotinamide riboside chloride
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background as provided by the European Commission
The European Union legislation lists nutritional substances that may be used for nutritional
purposes in certain categories of foods as sources of certain nutrients.
The relevant Union legislative measures are:
– Regulation (EU) 2015/2283 of the European Parliament and the Council on novel foods.1
– Directive 2002/46/EC of the European Parliament and of the Council laying down
requirements for food supplements.2
On 14 May 2018, the company ChromaDex Inc., submitted a request to the European Commission
in accordance with Article 10 of Regulation (EU) No 2015/2283 to place on the Union market synthetic
form of Nicotinamide riboside as a novel food and to be added to the list of niacin forms specified in
Annex II of Directive 2002/46/EC as a source of niacin.
1.1.2. Terms of reference as provided by the European Commission
In accordance with Article 29(1)(a) of Regulation (EC) No 178/2002, the European Commission
asks the European Food Safety Authority to provide a scientific opinion:
– by carrying out the assessment for synthetic form of Nicotinamide riboside as a novel food in
accordance with Article 10(3) of Regulation (EU) 2015/2283, and
– following the outcome of the novel food assessment by evaluating the safety of Nicotinamide
riboside, when added for nutritional purposes to food supplements as a source of niacin, and
on the bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC.
1.2. Information on existing evaluations and authorisations
In 2002, the Scientific Committee on Food (SCF) published an opinion on the Tolerable Upper
Intake level (UL) for niacin (nicotinic acid (NA) and nicotinamide (NAM)) (SCF, 2002). An UL for NAM of
900 mg/day was established for adults, excluding pregnant and lactating women in view of the lack of
data for these population groups.
In 2014, the NDA Panel published an opinion on dietary reference values for niacin (EFSA NDA
Panel, 2014).
2. Data and methodologies
2.1. Data
The safety assessment of this novel food (NF) is based on data supplied in the application and
information submitted by the applicant following EFSA’s requests for supplementary information.
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/2469.3
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of a NF application (EFSA NDA Panel, 2016). As
indicated in this guidance, it is the duty of the applicant to provide all of the available (proprietary,
confidential and published) scientific data (including both data in favour and not in favour) that are
pertinent to the safety of the NF.
1 Regulation (EU) 2015,2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending
Regulation (EU) No 1169.’2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258:97 of the
European Parliament and of the Council and Commission Regulation (EC) No 1852/2001 (0J L 327, 11.12.2015, p. 1).
2 Directive 2001,16/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the
Member States relating to food supplements (0.11, 183, 12.7.2002, p. 51).
3 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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This NF application includes a request for protection of proprietary data in accordance with Article 26
of Regulation (EU) 2015/2283. The data requested by the applicant to be protected comprise: an
in vitro study evaluating the metabolism of nicotinamide riboside in blood (Study No. 160312); an oral
7-day dose range finding toxicity study in juvenile dogs (Study No. SN17-921); a hERG screening assay
(Study No. 20151223); a 28-day repeat-dose oral toxicity study in juvenile dogs (Study No. SN17-940);
a 90-day repeated-dose oral toxicity study in Sprague–Dawley rats (Study No. S14022); a reproductive
toxicity study (Study No. G10959) and a developmental toxicity study (Study No. G10957) in rats.
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA NDA
Panel, 2016) and the principles described in the relevant existing guidance documents from the EFSA
Scientific Committee. The legal provisions for the assessment are laid down in Article 11 of Regulation
(EU) 2015/2283 and in Article 7 of the Commission Implementing Regulation (EU) 2017/2469.
This assessment concerns only risks that might be associated with the consumption of the NF
under the proposed conditions of use and is not an assessment of the efficacy of the NF with regard
to any claimed benefit.
The evaluation of the bioavailability of the nutrient (NAM, a form of niacin) from the source
(nicotinamide riboside chloride) was conducted in line with the principles contained in the Guidance on
safety evaluation of sources of nutrients and bioavailability of nutrient from the sources (EFSA ANS
Panel, 2018).
3. Assessment
3.1. Introduction
The proposed NF, nicotinamide riboside chloride, is a synthetic form of nicotinamide riboside,
proposed to be used in food supplements as a source of niacin. The target population is the general
adult population.
The NF falls under the following category, as defined in Art. 3 of Reg. EU 2015/2283: ix) Vitamins,
minerals and other substances used in accordance with Directive 2002/46/EC, Regulation (EC)
No 1925/2006 or Regulation (EU) No 609/2013.
3.2. Production process
The NF is produced according to Good Manufacturing Practice (GMP) and Hazard Analysis Critical
Control Points (HACCP) principles.
The NF is synthesised in a two-step process. First, the starting material, D-ribofuranose tetraacetate
is reacted at low temperature with hydrochloric acid to generate D-ribofuranose triacetate chloride.
When the reaction is complete, as verified by nuclear magnetic resonance (NMR), NAM is added to the
mixture, which is then stirred until the reaction to nicotinamide-b-ribofuranoside triacetate chloride is
complete.
The filter-cake is then analysed for nicotinamide-b-ribofuranoside triacetate chloride and held for
use in Step 2 of the reaction.
In the second step, the nicotinamide-b-ribofuranoside triacetate chloride is deacetylated and
washed with methanol and acetone to yield nicotinamide-b-ribofuranoside chloride (called from now on
nicotinamide riboside chloride).
Depending on the quality of the finished product, the NF can be reprocessed by recrystallisation in
methanol and/or further slurry in acetone. The product is off-loaded, vacuum-dried and transferred
directly to food-grade high-density polyethylene (HDPE) drums doubly-lined with an inner food-grade
low-density polyethylene (LDPE) liner.
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
3.3. Identity of the NF
The proposed NF contains ≥ 90% nicotinamide riboside chloride, predominantly in its b form, the
remaining components being residual solvents, reaction by-products and degradation products.
Nicotinamide riboside chloride
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2019;17(8):5775
Nicotinamide riboside chloride is registered with CAS number 23111-00-4 and EC number 807-820-5. Its
IUPAC name is 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;
chloride. The molecular formula of nicotinamide riboside chloride is C11H15N2O5Cl, and its molecular weight
290.7 g/mol. Themolecular structure of nicotinamide riboside chloride is reported in Figure 1.
To confirm the identity of the NF, the applicant provided analyses by high-performance liquid
chromatography coupled with ultraviolet/visible spectroscopy (HPLC UV-Vis), electrospray ionisation
mass spectrometry (ESI-MS), and mono- and two-dimensional NMR.
The NMR spectra of five lots of the NF performed in D2O, showed that all expected proton and
carbon shifts were present and that the nicotinamide riboside chloride conformed to the b-anomer.
The particle size distribution of five lots of the NF was determined using a Ro-Tap sieve shaker. The
observed batch-to-batch variability appears to be dependent on a variety of factors including the
production equipment and whether or not the batch was reprocessed (see Section 3.2).
The crystallinity of five lots of the NF was observed using a polarisation microscope and a digital
camera. The crystals were not uniform in size or colour, which is attributed primarily to the production
equipment and whether or not the batch was reprocessed.
3.4. Compositional data
The NF is composed primarily of nicotinamide riboside chloride (≥ 90%) together with residual raw
materials, residual solvents, reaction by-products, degradants and heavy metals.
In order to confirm that the manufacturing process is reproducible and adequate to produce on a
commercial scale a product with the required characteristics, the applicant provided analytical
information for five independent batches of the NF (see Table 1).
Figure 1: Molecular structure of nicotinamide riboside chloride
Table 1: Analytical data for five lots of the NF
Analyte
Lot Number
40C910-
16214-81
40C910-
17201-81
40C910-
17202-81
40C910-
17203-92
40C910-
17205-21
Nicotinamide riboside
chloride (% wt)
97.9 99.9 98.1 97.1 96.0
Nicotinamide (% wt) 0.24 0.25 0.25 0.35 0.33
Acetamide (mg/kg), < LOQ < LOQ < LOQ < LOQ < LOQ
Water content (% wt) ND 0.1 0.1 0.1 0.2
Chloride (%) 12 12 12 12 11
Acetic acid (mg/kg) ND 142 145 < LOQ 137
Acetone (mg/kg) 953 735 874 955 2020
Acetonitrile (mg/kg) 19 ND ND ND ND
Methanol (mg/kg) 199 170 186 148 379
Methyl acetate (mg/kg) ND < LOQ < LOQ < LOQ 19
Nicotinamide riboside chloride
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Information was provided on the accreditation of the laboratories that conducted the analyses
presented in the application.
The solvents used for the manufacturing (acetone, methanol, acetonitrile, and methyl t-butyl
ether), as well as acetic acid and methyl acetate, which are formed during the process, were below
their specification limits (see Section 3.5).
The Panel considers that the information provided on the composition of the NF is sufficient and
does not raise safety concerns.
3.4.1. Stability
Three studies have been conducted in order to evaluate the stability of the NF under real-time
conditions (25  2°C and 60  5% relative humidity (RH)), three studies under accelerated conditions
(40  2°C and 75  5% relative humidity) and two forced degradation studies. The NF was found to
be stable for at least 36 months, when stored under ambient conditions. Based on the data available,
the applicant recommends that the NF is stored under refrigerated conditions with a shelf-life of
36 months.
The Panel considers that the data provided are sufficient to establish the stability of the NF.
3.5. Specifications
The specifications of the NF as proposed by the applicant are indicated in Table 2.
Analyte
Lot Number
40C910-
16214-81
40C910-
17201-81
40C910-
17202-81
40C910-
17203-92
40C910-
17205-21
Methyl t-butyl ether
(mg/kg)
ND ND ND ND ND
Arsenic (mg/kg) < 0.2 < 0.2 < 0.2 < 0.2 < 0.2
Mercury (mg/kg) < 0.025 < 0.025 < 0.025 < 0.025 < 0.025
Cadmium (mg/kg) < 0.049 < 0.05 < 0.049 < 0.05 < 0.05
Lead (mg/kg) < 0.049 < 0.05 < 0.049 < 0.05 < 0.05
Total plate count < 10 CFU/g < 10 CFU/g < 10 CFU/g < 10 CFU/g < 10 CFU/g
Yeast and mould < 10 CFU/g < 10 CFU/g < 10 CFU/g < 10 CFU/g < 10 CFU/g
Escherichia coli Absent/10 g Absent/10 g Absent/10 g Absent/10 g Absent/10 g
Wt: weight; ND: not detected; LOQ: limit of quantitation; CFU: colony forming units.
Table 2: Specifications of the NF
Parameter Specifications Method
Colour White to Light Brown Visual
Form Powder Visual
Identification Conforms by NMR NMR
Nicotinamide riboside chloride ≥ 90 wt % HPLC-UV*
Water content ≤ 2.0 % Karl Fischer Titration (USP <921>)*
Residual solvents
Acetone ≤ 5,000 mg/kg GC Headspace (USP <467>)
Methanol ≤ 1,000 mg/kg GC Headspace (USP <467>)
Acetonitrile ≤ 50 mg/kg GC Headspace (USP <467>)
Methyl tert-butyl ether ≤ 500 mg/kg GC Headspace (USP <467>)
Reaction by-products
Methyl acetate ≤ 1,000 mg/kg GC Headspace (USP <467>)
Acetamide ≤ 27 mg/kg GC-FID*
Acetic acid ≤ 5,000 mg/kg GC-FID*
Nicotinamide riboside chloride
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Although the average nicotinamide riboside chloride purity of the NF is approximately 96% at the
time of the production, a specification of not less than 90% has been set to account for the degradation
of nicotinamide riboside chloride over the course of shelf-life. Specifications have also been set to
control the amount of residual solvents, reaction by-products, and heavy metals. Forced degradation
studies indicate that during shelf-life NF-containing products will accumulate small amounts of NAM,
ribose and chloride: these have not been included in the specifications because of no safety concern.
The Panel considers that the information provided on the specifications of the NF is sufficient and
does not raise safety concerns.
3.6. History of use of the NF and/or of its source
The NF has a generally recognized as safe (GRAS) status in the USA since 2016 for addition to
vitamin waters, protein shakes, nutrition bars, gum and chews, as a source of niacin.4 The intended
maximum use level is 0.027% by weight. It was also filed to the U.S. Food and Drug Administration as
a new dietary ingredient (NDI) for use in dietary supplements in 2015 (daily dose: 180 mg), without
objection5; the NDI status was updated in 2017 with new proposed intake level (daily dose 300 mg)
and product specifications.6
In 2018, the NF was included in the Licensed Natural Health Products Database (LNHPD) by Health
Canada.7
3.7. Proposed uses and use levels and anticipated intake
3.7.1. Proposed uses and use levels
The NF is proposed to be used as a source of niacin in food supplement capsules at levels up to
300 mg/day. The NF is intended for use by the general healthy adult population, including pregnant
and lactating women.
3.7.2. Anticipated intake of the NF
The applicant proposes that the NF should be consumed up to a maximum of 300 mg/day.
3.7.3. Combined intake from the NF and other sources
The information on the food sources of nicotinamide riboside is scarce. The applicant provided a
publication assessing the presence of NAD+ precursors in cow’s milk (Trammell et al., 2016b); average
concentrations of nicotinamide riboside ranging from 1.9 to 3.1 were reported, depending on the milk
production system. Based on these findings, the applicant estimated that the amount of nicotinamide
riboside ingested by humans from the equivalent of 710 mL/day of cow’s milk is 545 lg/day.
Parameter Specifications Method
Heavy metals
Arsenic ≤ 1 mg/kg ICP-MS (USP <232>, <233>, <2232>)
Mercury ≤ 0.1 mg/kg ICP-MS (USP <232>, <233>, <2232>)
Cadmium ≤ 1 mg/kg ICP-MS (USP <232>, <233>, <2232>)
Lead ≤ 0.5 mg/kg ICP-MS (USP <232>, <233>, <2232>)
Microbiological limits
Total plate count ≤ 1,000 CFU/g AOAC or equivalent
Yeast and mould ≤ 100 CFU/g AOAC or equivalent
Escherichia coli Absent/10 g AOAC or equivalent
AOAC: Association of Analytical Communities; CFU: colony forming units; GC-FID: gas chromatography coupled with a flame
ionisation detector; HPLC-UV: high-performance liquid chromatography-ultraviolet spectroscopy; ICP-MS: inductively coupled
plasma mass spectrometry NMR: nuclear magnetic resonance; USP: United States Pharmacopeia.
*: In-house validated analytical methods.
4 GRAS No 635, available at https://www.accessdata.fda.gov/scripts/fdcc/index.cfm?set=GRASNotices&id=635
5 NDIN 882, available at https://www.regulations.gov/document?D=FDA-2015-S-0023-0087
6 NDIN 1062, available at https://www.regulations.gov/document?D=FDA-2018-S-0023-0032
7 NPN 80088977, available at https://health-products.canada.ca/lnhpd-bdpsnh/info.do?licence=80088977
Nicotinamide riboside chloride
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Micromolar amounts of nicotinamide riboside are reported to be present in milk-derived products, and
yeast-containing food products are presumed to be natural sources of nicotinamide riboside (Chi and
Sauve, 2013). From the information available, the Panel considers that the contribution of nicotinamide
riboside from food sources other than the NF is too small to be relevant for the safety assessment.
A dose of 300 mg/day of the NF would deliver 126 mg NAM per day, under the assumption that
the NF is fully metabolised (see Section 3.8).
Mean intakes of niacin from the background diet were estimated to range from 42.2 to 50.1 mg
niacin equivalents (NE) per day in adult men and 27.5 and 35.5 mg NE/day in adult women, across EU
countries (EFSA NDA Panel, 2014). Estimates of 95th percentile intakes were up to 78.2 mg NE/day in
adult men. These estimates were calculated considering the food contents of preformed niacin (i.e.
NAM and NA) as well as of tryptophan (i.e. tryptophan content divided by a factor of 60).
3.7.4. Estimate of exposure to undesirable substances
The Panel identifies no concern from the information provided on the exposure to undesirable
substances, as the large majority of the remaining substances from the production process are
commonly found in food and the level of exposure to undesirable substances is considered not to pose
any safety concern.
3.8. Absorption, distribution, metabolism and excretion (ADME)
The applicant provided study reports which investigated the concentration of nicotinamide riboside or its
metabolites in plasma, white blood cells (WBCs) and urine following administration of the NF in rats (Avery,
2017), dogs (Thorsrud, 2017, 2018) and humans (Wilson, 2015; Trammell et al., 2016a; Schacter, 2018;
Conze et al., 2019). Table 3 provides an overview of the dose levels of the NF and the main metabolites
investigated. Upon EFSA’s request about the form(s), mechanism(s), and efficiency of absorption of the NF,
the applicant also conducted a systematic search in PubMed to retrieve relevant studies.
Animal data
In a rat study investigating the digestion and absorption of labelled NAD, NAD was found to be
rapidly hydrolysed to nicotinamide riboside in the intestine (Gross and Henderson, 1983). Further
results indicated that nicotinamide riboside was hydrolysed to NAM by an enzyme associated with the
mucosal cells before absorption (Baum et al., 1982; Gross and Henderson, 1983). Increasing the NAD
dose was associated with a decrease in the percentage of labelled products removed from the
intestine and a decrease in the percentage of nicotinamide riboside that was converted to NAM. The
uptake of [14C]-carboxamide-labelled NAD was compared to the uptake of [14C]NAM and was found to
be slower (24% vs 80% in 15 min). This study indicates that, in rats, nicotinamide riboside is
converted to NAM before absorption and that this reaction is a rate-limiting step.
Following the administration of 2H- and/or 13C-labelled nicotinamide riboside to mice by oral gavage
(50 mg/kg body weight (bw)), nicotinamide riboside was not detected in blood, while the blood
concentration of NAM increased from 2 lM at baseline to 6 lM at the last measurement time point, 135 min
after administration (Liu et al., 2018). Examination of tissue NAD+ labelling indicated that a small fraction of
doubly-labelled nicotinamide riboside was assimilated in the NAD+ liver pool. Minimal assimilation of doubly-
labelled nicotinamide riboside was detected in the NAD+ pool of extrahepatic tissues. This study indicates
that, in mice, a small fraction of nicotinamide ribosidemight be absorbed as NAM in the intestine.
Studies in mice were conducted to compare the increase in hepatic NAD+ concentrations following
the administration of the NF (185 mg/kg bw) or equimolar amounts of NA or NAM by oral gavage
(Trammell et al., 2016a). Both the NF and NAM increased hepatic NAD+ concentrations to levels
greater than NA. The NF and NAM administration resulted in increased hepatic concentrations of NAM,
1-methylnicotinamide (1-MN) and N-methyl-4-pyridone-carboxamide (4-PY), although the maximum
concentration achieved (Cmax) and area under the curve (AUC) for these metabolites differed between
the NF and NAM groups. In mice receiving the NF, increases in liver concentrations of nicotinamide
mononucleotide (NMN), nicotinic acid adenine dinucleotide (NaAD) and nicotinic acid mononucleotide
(NAMN) were also observed. The Panel notes that, in mice, the kinetics of the NF and NAM
metabolisms differed but results indicate that the NF is metabolised to the same metabolites as NAM.
In the toxicokinetic (TK) arm of the 90-day subchronic toxicity study in rats (Avery, 2017) (see
Section 3.10.2), blood samples were collected before and 0.5, 1, 2, 4, 6, 8, 12 and 24 h after oral
administration of 1,000 mg/kg bw per day of the NF (NF group) or an equimolar dose of NAM (420
mg NAM/kg bw per day, NAM group) on days 1 and 90. NAM and 1-MN were measured in plasma. On
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day 1, plasma NAM concentration peaked considerably later (time at which the Cmax is observed (Tmax)
males: 6.0  0.0 vs 0.67  0.17 h; Tmax females: 6.7  0.7 vs 1.0  0.0 h) and at a lower level
(Cmax males: 154.8  13.9 vs 249.8  8.6 lg/mL; Cmax females 118.7  1.6 vs 385.4  15.6 lg/mL)
in the NF group than in the NAM group. Systemic exposures to NAM were lower in the NF group than in
the NAM group (AUClast male: 1,271.3  121.7 vs 1,713.0  26.1 h*lg/mL; AUClast females:
882.4  109.3 vs 1,872.7  56.8 h*lg/mL). Similar patterns were observed on day 90 although the
values reached were higher than on day 1 in both groups (AUClast male: 2,222.5  113.8 vs
4,146  132.6 h*lg/mL; AUClast females: 1,931.5  80.8 vs 3,118.5  69.8 h*lg/mL). On days 1 and
90, plasma NAM concentrations 24 h after dosing were comparable to those before dosing in both
groups. On day 1, the plasma concentration of 1-MN increased within 1 h of dosing and reached similar
maximum concentrations in both groups (Cmax males (mean  SEM): 4.4  1.3 vs 3.5  0.2 lg/mL;
Cmax females: 2.6  0.2 vs 2.5  0.1 lg/mL). Systemic exposures to 1-MN were similar in both groups
(AUClast males: 62.5  3.0 vs 70.2  1.2 h*lg/mL; AUClast females: 39.4  0.9 vs 41.2  0.9 h*lg/
mL). Similar patterns were observed on day 90; however, the basal (T0) plasma concentration of 1-MN
was higher on day 90 than on day 1 in both groups. The Panel notes that, in rats, ingestion of the NF
resulted in slower plasma appearance of NAM and lower systemic exposure, as compared to NAM
ingestion. Administration of the NF results in rapid appearance of its metabolite, 1-MN, in plasma, with
kinetic characteristics similar to that following NAM administration. At the tested dose levels, both NF and
NAM administration resulted in increase of 1-MN in plasma at the end of the 90-day period.
In an oral 7-day dose range finding toxicity study in juvenile Beagle dogs (Thorsrud, 2017), daily
doses of 100, 300 and 1,000 mg/kg bw per day of the NF were administered by gavage (n = 2 per
group). On day 7, plasma was collected 2 h after dosing. The plasma 1-MN concentration increased
dose dependently in males (mean  SD: 416  100, 604  46 and 856  66 ng/mL). Corresponding
concentrations in females were 449  71, 818  221 and 575  21 ng/mL. There was no control
group in that study. The applicant indicates that concentrations of 1-MN between 8.3 and 34 ng/mL
were reported in plasma samples of untreated Beagle dogs (method validation report by Chen (2017)).
The Panel notes that this study indicates that, in dogs, oral administration of the NF results in the
appearance of its metabolite, 1-MN, in plasma.
In a TK study conducted as part of a 28-day toxicity study in Beagle dogs (Thorsrud, 2018), daily doses
of 0, 100, 300 and 1,000 mg/kg bw per day of the NF were administered by gavage (n = 2 per group).
Plasma was collected 0, 0.5, 1, 3, 8 and 24 h post-dose, both on days 1 and 28. On day 1, an increase in
plasma concentrations of 1-MN was detected at the first time point (0.5 h) and following time points, in all
dose groups compared to the control (Cmax males (mean  SD): 141  35, 901  50, 1,004  142,
789  725 ng/mL; Cmax females: 117  1, 860  27, 983  81, 1,072  130 ng/mL). Systemic
exposure increased with increasing doses of the NF (AUClast males: 2,827  582, 14,154  449,
21,743  3,467, 17,888  16,728 h*ng/mL; AUClast females: 2,428  55, 17,023  2,353,
24,424  942, 22,783  2,407 h*ng/mL). Mean plasma 1-MN concentrations at time 0 on day 28
indicated an increase of the metabolite at the end of the 28-day period in all groups compared to the
control (males: 150, 502, 1,650 and 1,541 ng/mL, females: 159, 717, 1,706 and 1,766 ng/mL). On day 28,
systemic exposure increased with increasing doses of the NF and reached higher levels than on day 1
(AUClast males: 2,214  440, 25,331  4,780, 41,779  5,827, 38,247  17,201 h*ng/mL; AUClast
females: 2,645  35, 28,452  298, 42,256  5,406, 42,218  349 h*ng/mL). The Panel notes that this
study indicates that, in dogs, oral administration of the NF results in rapid appearance of its metabolite,
1-MN, in plasma. An increase of 1-MN in plasma occurred at the end of the 28-day period in all dose groups.
Similar systemic exposure levels of 1-MN were reached at 300 and 1,000 mg/kg bw.
Human data
In a single dose, randomised, double-blind, cross-over study of the pharmacokinetics of the NF in
12 healthy adults (Wilson, 2015; Trammell et al., 2016a), blood and urine samples were collected over
24 h following the ingestion of 100, 300 or 1,000 mg of the NF in capsules. There was no control
group in that study. No significant changes in nicotinamide riboside or NA concentrations were
detected in plasma or WBCs at any of the dose tested, at any time point. Compared to baseline, a
significant increase in plasma NAM concentration was detected in the high-dose group, but not in the
low- and mid-dose groups. No significant changes in NAM concentration in WBC were detected in any
group. Dose- and time-dependent increases in the concentrations of 1-MN, N-methyl-2-pyridone-
carboxamide (2-PY) and 4-PY in plasma were observed. The largest increases were detected for 2-PY
(Cmax (mean  SD): 3.5  1.3, 6.6  2.0, 17.0  5.0 lM, p < 0.001) and 4-PY (Cmax (mean  SD):
0.44  0.35, 0.90  0.37, 2.52  0.64 lM, p < 0.001), while the plasma concentration of 1-MN
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increased to a smaller extent (Cmax (mean  SD): 0.22  0.19, 0.43  0.33, 0.89  0.62 lM,
p < 0.001). For the three metabolites, the changes in WBC concentrations followed patterns
comparable to those in plasma. No changes in NAD+ or NADP concentrations were detected in either
plasma or WBC. Urinary concentrations of NAM, 1-MN, 2-PY and 4-PY significantly increased in the
group which received 1,000 mg of the NF, but not in the groups which received 100 and 300 mg of
the NF. A relative decrease in urine concentration of nicotinamide riboside was observed in all groups,
compared to pre-dose. No change in urine NA concentration was observed in any group.
Other metabolites were also analysed in this study. Increases of NaAD in WBC or nicotinic acid ribose
(NaR) in plasma were observed in the 300 mg and 1,000 mg groups at different time points whereas
significant time- and dose-dependent increases compared to pre-dose were observed in urine for all
treatment groups. There were significant time-dependent decreases in NMN in urine in all three groups
but no changes in WBC concentrations. No significant dose-related changes were observed for adenine
diphosphate ribose (ADPR) in plasma, cytidine uridine and uridine monophosphate (UMP) in plasma, WBC
and urine, inosine in plasma and WBC, and adenosine-diphosphate (ADP) in urine and plasma.
The Panel notes that ingestion of a single dose of 1,000 mg of the NF resulted in an increase of
NAM concentration in plasma, which was not observed at doses of 100 mg or 300 mg. 1-MN and to a
larger extent its oxidation products, 2-PY and 4-PY, increased dose- and time-dependently in both
plasma and WBC, while urinary concentrations of these metabolites were only increased at a dose of
1,000 mg. The relevance of observed changes at different time points in some of the other
metabolites measured such as NaAD in WBC, NaR in plasma and urine or NMN in urine is unclear.
In an 8-week randomised, double-blind, placebo-controlled, parallel group study (Schacter, 2018;
Conze et al., 2019), 140 (intention-to-threat (ITT)) or 128 (per-protocol (PP)) healthy subjects
ingested capsules containing either silicified microcrystalline cellulose (placebo) or 100, 300 or
1,000 mg/day of the NF (n = 30 per group) for 8 weeks. Fasting blood and urine samples were
collected at the end of weeks 1, 2, 4 and 8. In ITT analysis, there was a significantly higher plasma
NAM concentration in the high-dose group compared to the other groups at week 8 (22.3  11.5,
26.6  13.1, 27.9  9.6, 43.7  22.7 ng/mL in the control, low-, mid- and high-dose groups,
respectively). A significantly higher plasma concentration of 1-MN was found in the mid- and high-dose
groups compared to the control (3.1  2.3, 5.6  3.8, 10.1  5.0, 26.6  12.6 ng/mL in the control,
low-, mid- and high-dose groups, respectively). Significant increases in whole blood concentrations of
NAD+ were found in the mid-and high-dose group compared to the control group, after 1, 2 and
8 weeks of intervention. Maximum blood NAD+ concentrations were reached at week 2 (32.9  7.6
and 50.0  17.2 lg/mL in the mid- and high-dose groups, respectively) and plateaued thereafter. At
the end of the study, a significant dose-related increase was found in urinary 1-MN concentration
(4.1  1.9, 6.6  4.9, 10.6  16.1, 17.8  8.8 ng/lg creatinine for the control, 100 mg/day, 300 mg/
day and 1,000 mg/day NIAGEN dose groups, respectively; p < 0.001). Similarly, a significant dose-
related increase was found in urinary 2-PY concentration (15  7, 30  24, 51  55, 113  50 ng/lg
creatinine for the respective groups; p < 0.001). The concentrations of 1-MN and 2-PY were significantly
higher in the mid- and high-dose groups than in the control group. Results of the PP analyses were
comparable. The Panel notes that ingestion of 1,000 mg/day of the NF for 8 weeks resulted in an increase
of NAM concentration in plasma, which was not observed at doses of 100 mg/day or 300 mg/day. NAD+
concentration in whole blood significantly increased following administration of 300 and 1,000 mg/day
and reached a plateau after two weeks. 1-MN and its oxidation products increased dose dependently in
plasma and urine, indicating saturation of the NAM vitamin body pool and a higher plasma steady state
concentration of its metabolites.
Another study of pharmacokinetics of the NF in humans is available in the literature (Airhart et al.,
2017). The NF was orally administered to eight healthy volunteers, with gradual increments from a dose
of 250 mg/day on days 1 and 2 up to a dose of 2,000 mg/day on days 7 and 8. On day 9, subjects
received a dose of 1,000 mg of the NF and whole blood was sampled over 24 h for measurement of
nicotinamide riboside and NAD+ concentrations. Mean ( SD) basal concentration of nicotinamide
riboside was 0.023  0.007 lM on day 1 and 0.029  0.008 lM on day 9 (p = 0.07). A small transient
increase in nicotinamide riboside concentration was observed in four out of eight subjects, reaching a
maximum 3 h post-dose (0.05  0.03 lM, p = 0.04). Basal mean blood concentrations of NAD+ were
27  6 lM on day 1 and 50  20 lM on day 9 (p = 0.001). The Pearson correlation coefficient between
the changes in nicotinamide riboside and NAD+ concentrations between day 1 and day 9 was 0.85
(R2 = 0.72, p = 0.008). On day 9, no further change in NAD+ concentration was detected over the 24 h
post-dose. The Panel notes that in this study supplementation of the NF at doses up to 2,000 mg for
9 days significantly increased NAD+ concentrations in blood compared to baseline.
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Table 3: Overview of animal and human data on the metabolism of the NF
Reference Species Design Doses
PLASMA URINE
Notes
NR NAM 1-MN NA 2-PY 4-PY NAD+ NAM 1-MN 2-PY 4-PY
Avery (2017) Rat  90-day
subchronic
toxicity study
 Blood sampled
over 24-h post-
dose, on day 1
and day 90
1,000 mg/kg
bw per day
nd nd nd nd nd nd nd nd nd At the tested dose, 1-MN
reached a higher steady
state concentration in
plasma over the 90-day
period
Thorsrud
(2017)
Dog  7-day dose range
finding toxicity
study
 Blood sampled
2 h after dosing
on day 7
100
300
1,000
mg/kg bw
per day
nd nd (a) nd nd nd nd nd nd nd nd –
Thorsrud
(2018)
Dog  28-day
toxicokinetic
study
 Blood sampled
over 24-h post-
dose, on day 1
and day 28
0
100
300
1,000/500(b)
mg/kg bw
per day
nd nd ↔ nd nd nd nd nd nd nd nd  AUClast and Cmax similar
in the mid- and high-
dose groups on days 1
and 28 indicating a
saturation of the NF
absorption/metabolism
at the high-dose levels
 At all tested doses, 1-
MN reached a higher
steady state
concentration in plasma
over the 28-day period
Wilson
(2015) and
Trammell
et al.
(2016a)
Human  Single dose,
randomised,
double-blind,
cross-over
pharmacokinetics
study
 Blood and urine
sampled over
24 h post-dose
100
300
1,000 mg, as
single doses
↔
↔
↔
↔
↔
↔ ↔
↔
↔
↔ ↔ ↔
↔
↔
↔
↔
↔
↔
↔
↔
↔
↔
 At the high-dose level,
1-MN and its oxidation
products increased
significantly in urine,
indicating a saturation
of the nicotinamide
vitamin body pool
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Reference Species Design Doses
PLASMA URINE
Notes
NR NAM 1-MN NA 2-PY 4-PY NAD+ NAM 1-MN 2-PY 4-PY
Schacter
(2018) and
Conze et al.
(2019)
Human  8-week
randomised,
double-blind,
placebo-
controlled,
parallel group
study
 Fasting blood and
urine sampled at
the end of weeks
1, 2, 4 and 8
0
100
300
1,000 mg/day
nd ↔
↔
↔
↔
(c)
nd nd nd ↔
(c)
nd ↔
(c)
↔
(c)
nd At the mid- and high-dose
levels:
 NAD+ concentration
reached a plateau after
2 weeks
 1-MN and its oxidation
products increased
significantly in urine
 1-MN and NAD+
reached higher steady
state concentrations in
plasma over the 8-week
period
Airhart et al.
(2017)
Human  8-day open-
labelled
uncontrolled
study
 Blood sampled
pre-dose on day
1 and over 24 h
after a 1,000 mg
dose on day 9
Gradual
increase
from 250 on
day 1 to
2,000 mg/day
on day 8
↔(d) nd nd nd nd nd (d) nd nd nd nd  On day 9, increased NR
concentration was
detected 3 h post-dose
in 4 out of 8 subjects
 On day 9, no further
increase in NAD
+ was
detected over 24 h
post-dose
↑: increase in metabolite concentration; ↔: no relevant change in metabolite concentration; bw: body weight; 1-MN: 1-methylnicotinamide; 2-PY: N-methyl-2-pyridone-carboxamide; 4-PY: N-
methyl-4-pyridone-carboxamide; nd: not determined; NA: nicotinic acid; NAD+: nicotinamide adenine dinucleotide; NAM: nicotinamide; NR: nicotinamide riboside chloride.
(a): Compared to untreated Beagle dogs.
(b): Due to weight loss observed in males in the 1,000 mg/kg bw per day group, dosing was reduced to 500 mg/kg bw per day as of day 9 in females and day 10 in males. Thus, the high-dose
level was 1,000 mg/kg bw on day 1 and 500 mg/kg bw on day 28.
(c): Increase not statistically significant compared to control group.
(d): Day 9 vs day 1.
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In vitro data
To determine the metabolic fate of the NF in blood, an in vitro study was conducted (Guo, 2018)
(Study No. 160312) in which equal amounts of 13C- and deuterium-labelled nicotinamide riboside
chloride were added to water, heparinised whole blood, heparinised plasma, and serum at a
concentration of 39 lM. The nicotinamide riboside and NAM contents of the samples were analysed
immediately (T0) or after incubation at 37°C for 5 and 10 min. Compared to T0, there was no
significant change in the amount of nicotinamide riboside or NAM in water, plasma, and serum samples
over the course of the 10 min incubation period. In contrast, the amount of nicotinamide riboside in
whole blood decreased within 5 min, while the amount of NAM increased. Similar results were
obtained when the samples were incubated at 4°C, although the kinetics of the decrease in the
amount of nicotinamide riboside and increase in the amount of NAM in whole blood were delayed
compared to those observed at 37°C. Similar results have been reported by Liu et al. (2018). The
Panel notes that these results indicate that the NF can be metabolised to NAM in a cellular component
of whole blood.
In vitro data indicate that nicotinamide riboside can be hydrolysed to nicotinamide and ribose-1-
phosphate by a purine nucleoside phosphorylase (Rowen and Kornberg, 1951; Kornberg, 1955;
Nishizuka, 1971; Wielgus-Kutrowska et al., 1997), which is an ubiquitous enzyme in mammals
(Bzowska et al., 2000).
An alternative metabolic pathway for the contribution of nicotinamide riboside to NAD+ pool,
independent from the NAM pathway, has been described in yeast in which nicotinamide riboside was
found to act as a precursor for NAD+ through its conversion into NMN via the action of a nicotinamide
riboside kinase (Nrk), (Bieganowski and Brenner, 2004). NrK genes were identified in the human
genome.
Fate of the ribosyl moiety
Upon EFSA’s request about the metabolic fate of the ribosyl moiety, the applicant indicated that,
after being released from the NF, ribose is expected to be converted to ribose-1-phosphate and enter
the pentose phosphate pathway for nucleotide-base salvage or generation of glyceraldehyde-3-
phosphate and fructose-6-phosphate which can be used as energy source via glycolysis. Assuming a
daily intake of 300 mg of the NF, the maximum resulting exposure to free ribose would be 145 mg/day
or 2.1 mg/kg bw per day for a 70-kg adult. In 2018, the EFSA NDA Panel adopted the Scientific
Opinion on the safety of D-ribose as a novel food and concluded that D-ribose is safe for the general
population at intake levels up 36 mg/kg bw per day (EFSA NDA Panel et al., 2018).
Conclusions on ADME
Altogether, the Panel notes that the NF is likely to be absorbed mainly as NAM following hydrolysis
in the gut. In case a fraction of the NF would be absorbed intact, it is expected to be rapidly
metabolised to NAM in the blood. NAM acts as a precursor of NAD+ in cells and is primarily
metabolised in the liver to 1-MN through methylation and subsequently to 2-PY, and 4-PY, following
oxidation. In the 8-week supplementation study in humans, a gradual and significant increase in whole
blood concentration of NAD+ was found with doses of 300 mg and 1,000 mg/day of the NF. The single
dose pharmacokinetic study and the 8-week supplementation studies in humans indicated that 1-MN,
2-PY and 4-PY concentrations increase in a time- and dose-dependent fashion in plasma, WBCs and
urine following ingestion of 100–1,000 mg/day of the NF. Dose-dependent increases in the plasma
concentration of 1-MN were also reported in rats and dogs following ingestion of the NF. The
Panel notes that at doses of 300 mg and 1,000 mg/day of the NF for 8 weeks, the concentrations of
NAD+ and 1-MN in human plasma were higher than in the control group and increases in urinary
excretion of 1-MN and 2-PY were observed, indicating a saturation of NAM vitamin body pool.
3.9. Nutritional information
The NF is proposed to be used as a source of niacin. Niacin is a generic term for NA and NAM,
which are water-soluble organic compounds that belong to the group of B vitamins and are present in
a wide range of foods (EFSA NDA Panel, 2014). Niacin can be synthesised in the human body from the
amino acid tryptophan. The NDA Panel set average requirement (AR) and population reference intake
(PRI) for niacin of, respectively, 1.3 mg niacin equivalent (NE8)/MJ and 1.6 NE mg/MJ for all population
8 1 mg NE = 1 mg nicotinamide = 1 mg nicotinic acid = 60 mg tryptophan.
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groups. Dietary reference values (DRV) were expressed on a MJ basis, considering that the niacin
requirement depends on energy intake. In adults, the PRIs range from 10.5 mg NE/day for women
aged 70–79 years with a sedentary lifestyle (physical activity level (PAL) = 1.4) to 21.8 mg NE/day for
men aged 18–29 years with very active lifestyle (PAL = 2.0) (EFSA NDA Panel, 2014). The Panel notes
that, at the proposed maximum use level of 300 mg/day, the NF would deliver 126 mg NAM/day under
the assumption that nicotinamide riboside chloride is fully metabolised (Section 3.8), which largely
exceeds the physiological requirement for niacin.
The SCF set a UL for NAM of 900 mg/day (12.5 mg/kg bw) for the adult population, excluding
pregnant and lactating women (SCF, 2002). To derive the UL, the SCF considered that no significant
adverse effects had been reported in trials on NAM supplementation in patients with or at risk of
diabetes, which had received doses up to the equivalent of 3 g per day for periods up to 3 years. A no
observed adverse effect level (NOAEL) of 25 mg/kg bw per day was derived from these studies. The
SCF noted that these trials used sensitive markers of hepatic function and glucose homeostasis, and
included a range of age groups, with some subjects treated with up to 50 mg/kg bw per day. An
uncertainty factor (UF) of 2 was applied to the NOAEL to allow for the fact that adults may eliminate
NAM more slowly than the study groups, many of which were children, and that data for children
would not reflect the full extent of inter-subject variability that could occur in an older population. The
SCF stated that the UL of 900 mg/day for NAM was not applicable during pregnancy or lactation
because of inadequate data relating to this critical life stage.
Based on the NOAEL of 25 mg/kg bw derived from the same studies, the UK Expert Group on
Vitamins and Minerals proposed a guidance value of 8.3 mg NAM/kg bw (Expert Group on Vitamins
and Minerals, 2003), which corresponds to 580 mg/day for a 70-kg adult. In deriving this value, the
expert group applied an UF of 3 to account for interindividual variability, in view of the nature of the
study populations and the small numbers of subjects involved.
High intakes of niacin are not known to inhibit the absorption or modify bioavailability of other
nutrients. The Panel notes that available toxicological studies in rats and dogs and human studies on
the NF do not specifically address such effects.
The Panel considers that consumption of the NF is not nutritionally disadvantageous.
3.10. Toxicological information
The applicant provided several toxicological studies on the NF. These studies are listed in Table 4.
Table 4: Summary of toxicological studies with the NF
Test item Reference Type of study Test system Dose
NF Study No. S15004
(Unpublished)
(Kamath, 2015; Conze et al.,
2016)
Bacterial reverse mutation
test (GLP, OECD TG 471)
Salmonella
Typhimurium and
Escherichia coli
Up to 5 mg/plate
(absence and
presence of S9 mix)
NF Study No. S15005
(Unpublished)
(Conze et al., 2016; Kamath,
2016)
In vitro mammalian
chromosome aberration
test (GLP, OECD TG 473)
Human peripheral
blood lymphocyte
Up to 5 mg/mL
NF Study No. S15006
(Unpublished)
(Conze et al., 2016; Pandey,
2016)
In vivo mammalian
erythrocyte micronucleus
test (GLP, OECD TG 474)
Sprague–Dawley
rats
Up to 2,000 mg/kg
bw
NF Study No. 20151223
(Unpublished)
hERG screening assay
(non-GLP)
Human embryonic
kidney 293 cells
Up to 1.03 mM
NF Study No. S13101
(Unpublished)
(Bhoite and Jayachandra,
2014b; Conze et al., 2016)
Single dose oral toxicity
study (GLP)
Sprague–Dawley
rats
5,000 mg/kg bw
NF Study No. SN17-921
(Unpublished)
(Thorsrud, 2017)
7-day dose range finding
oral toxicity study (GLP)
Juvenile dogs Up to 1,000 mg/kg
bw per day
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3.10.1. Genotoxicity
The applicant provided the results of a bacterial reverse mutagenicity test, an in vivo mammalian
erythrocytemicronucleus test and an in vitromammalian chromosome aberration test performedwith the NF.
In a bacterial reverse mutagenicity test (Study No. S15004, unpublished, GLP, OECD TG 471;
(Kamath, 2015; Conze et al., 2016)) with Salmonella Typhimurium TA98, TA100, TA1535 and TA1537
and Escherichia coli strain WP2 uvrA (pKM101) the NF did not increase the number of revertant
colonies in any of the tester strains at concentration up to 5,000 lg/plate, either when incubated in
the presence or absence of a metabolic activation system or using the plate incorporation or
preincubation methods. The results of the study indicated that the NF is non-mutagenic.
In an in vitro mammalian chromosome aberration test with human peripheral blood lymphocytes
(HPBLs) (Study No. S15005, unpublished, GLP, OECD TG 473; (Conze et al., 2016; Kamath, 2016)), no
increase in the number or type of aberrant metaphases was detected up to 5 mg/mL, either in the
presence or absence of a metabolic activation system. No cytotoxicity was observed at any
concentration. The results of the study indicated that the NF is not clastogenic at doses up to 5 mg/mL.
In an in vivo mammalian erythrocyte micronucleus test with Sprague–Dawley rats (Study No.
S15006, unpublished, GLP, OECD TG 474; (Conze et al., 2016; Pandey, 2016)), the NF had no effect
on the percentage of polychromatic erythrocytes with micronuclei or on the mean polychromatic
erythrocyte/total erythrocyte (P/E) ratio compared to the vehicle control 24 or 48 h after a single dose
of 500, 1,000 and 2,000 mg/kg bw. In view of the ADME data in rats (see Section 3.10.2), it can be
assumed that the target, the bone marrow has been reached. The results of the study indicated that
the NF is non-cytotoxic and does not induce micronuclei.
Even though the genotoxicity testing strategy is not fully in line with current EFSA recommendations
(EFSA Scientific Committee, 2011), as no in vitro mammalian micronucleus test was provided, in view of
the nature of the test substance, the Panel considers that there are no concerns regarding genotoxicity of
the NF.
3.10.2. Acute, subacute and subchronic toxicity studies
The applicant provided several toxicity studies performed with the NF: a single dose oral toxicity study
in rats, a 7-day dose range finding toxicity study in juvenile dogs, a 14-day dose range finding toxicity
study in rats, a 28-day toxicity study in juvenile dogs and a 90-day repeated dose toxicity study in rats.
In an acute toxicity study in rats (Study No. S13101, unpublished, GLP (Bhoite and Jayachandra,
2014b; Conze et al., 2016), five male and female Sprague–Dawley rats were administered 0 or
5,000 mg/kg bw of the NF as a single dose by oral gavage. The only finding was a significantly lower
cumulative body weight gain in female rats (3%) compared to control group.
Test item Reference Type of study Test system Dose
NF Study No. S13120
(Unpublished)
(Bhoite and Jayachandra,
2014a; Conze et al., 2016)
14-day dose range finding
oral toxicity study (non-
GLP)
Sprague–Dawley
rats
Up to 5,000 mg/kg
bw per day
NF Study No. SN17-940
(Unpublished)
(Thorsrud, 2018)
28-day oral toxicity study
(GLP)
Juvenile dogs Up to 1,000 mg/kg
bw per day
NF and
nicotinamide
Study No. S14022
(Unpublished)
(Bhoite et al., 2015; Conze
et al., 2016)
90-day repeated dose
oral toxicity study (GLP,
OECD TG 408)
Sprague–Dawley
rats
Up to 3,000 mg/kg
bw per day
NF Study No. G10959
(Unpublished)
(Ganiger, 2016)
One generation
reproduction toxicity
study (GLP, OECD TG
415)
Sprague–Dawley
rats
Up to 12,000 mg/kg
in the diet
(ad libitum)
NF Study No. G10957
(Unpublished)
(Geetha Rao, 2016)
Embryo-fetal
developmental toxicity
study (GLP, OECD TG
414)
Sprague–Dawley
rats
Up to 1,500 mg/kg
bw per day
bw: body weight; GLP: Good Laboratory Practice; OECD: Organisation for Economic Co-operation and Development; hERG:
human ether-ago-go-related gene.
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In a 7-day dose range finding oral toxicity study (Study No. SN17-921, unpublished, GLP (Thorsrud,
2017)), the NF was administered to groups of male and female juvenile dogs (2/sex per group) for
7 days via oral gavage at dose levels of 100, 300, and 1,000 mg/kg bw per day, respectively. No
toxicologically relevant findings were observed in any of the groups tested.
In a 14-day dose range finding oral toxicology study (Study No. S13120, unpublished, non-GLP
(Bhoite and Jayachandra, 2014a; Conze et al., 2016)), the NF was administered to five groups of male
and female Sprague–Dawley rats (5/sex per group) for 14 days by oral gavage at dose levels of 0,
750, 1,500, 2,500 or 5,000 mg/kg bw per day, respectively. The only relevant finding was a reduction
in mean body weight in relation to the control group observed in male rats administered 1,500, 2,500
and 5,000 mg/kg bw per day at different time points (all < 10%) and a decrease in overall food
consumption in male rats administered 5,000 mg/kg bw per day (8%).
In a 28-day repeated dose toxicity study (Study No. SN17-940, unpublished, GLP (Thorsrud,
2018)), the NF was administered to six groups of male and female juvenile dogs (test animals: 4/sex
per group; TK satellite animals: 2/sex per group) for 28 days by oral gavage at dose levels of 0, 100,
300 and 1,000 mg/kg bw per day, respectively. Because of decreased body weights and adverse
clinical findings in the animals dosed at the highest level, the high dose was decreased from 1,000 to
500 mg/kg bw per day (on day 9 for females and on day 10 for males). The evaluation included
clinical observations, body weight, body weight gain and qualitative feed consumption. Clinical
pathology parameters reported for core animals included haematology, clinical chemistry, coagulation
and urinalysis. The core animals were sacrificed, a full gross necropsy was performed, and tissues
were collected for organ weights and histopathology. In addition, blood samples were collected on the
first and last day of dosing for evaluation of the metabolite, 1-MN, in satellite TK animals. The results
of this part of the study are described in Section 3.8. Effects that are considered as substance related
are summarised in Table 5. Clinical findings observed at 1,000 mg/kg bw included salivation after
dosing, abdominal contractions, diarrhoea, vomiting and reduced body weight. After lowering the dose
to 500 mg/kg bw, still salivation and vomiting occurred, and several other parameters were affected.
In the male dogs, glucose, sodium, potassium, prothrombin time, eosinophils, absolute and relative
testes and thyroid weights were decreased. In female dogs, AST was increased, phosphate decreased,
albumin and fibrin decreased. Increases in glucose concentrations in the mid-dose group and
decreases in prothrombin time in the mid- and low-dose groups were not very pronounced and not
clearly dose related. Therefore, overall, the NOAEL in juvenile dogs was 300 mg/kg bw per day.
3.10.2.1. 90-day study
In a 90-day repeated dose toxicity study in male and female Sprague–Dawley rats (Study
No. 14022, unpublished, GLP, OECD TG 408; (Bhoite et al., 2015; Conze et al., 2016)), the NF was
administered by gavage at doses of 0, 300, 1,000 or 3,000 mg/kg bw per day to 10 male and female
Sprague–Dawley rats per group. One additional group was administered NAM at 1,260 mg/kg bw
which was equimolar to 3,000 mg/kg bw of the NF. The results of the TK part of this study are
described in Section 3.8.
Effects that are considered as substance-related are summarised in Table 5. Compared to controls,
lower body weights were noted in all male rats that received the test items. The effect was dose
related (8%, 9%, 17%) after 90 days, and statistically significant at several time points
throughout the study for all dose levels. No effect was found for female rats (0, 5%, 2%). Feed
consumption was decreased in male rats at 3,000 mg/kg bw per day of the NF (9-14%). Isolated
decreases in feed consumption were observed at 300 and 1,000 mg/kg bw per day of the NF in male
rats. The Panel notes that the effects on body weight are related to reduced food consumption and
not very pronounced in the low and mid dose and are therefore not considered as adverse.
While the slight effects on body weight and food consumption were the only effects at 300 mg/kg
bw, numerous effects were found at 1,000 and 3,000 mg/kg bw, which are summarised in Table 5.
They refer to haematology, liver, kidneys and the hormonal system/genital organs. The number and
magnitude of effects increase considerably from the mid- to the high-dose group, indicating a steep
dose–response relationship. At 3,000 mg/kg bw in several organs also findings in histopathological
examinations are reported. The Panel notes that with 1,260 mg/kg bw NAM, equimolar to 3,000 mg/kg
bw nicotinamide riboside chloride, the same effects occurred as for the NF. Only the effect sizes differed
slightly and were sometimes higher or lower with NAM compared to the NF.
Based on the results of this study, the NOAEL is 300 mg/kg bw.
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Table 5: Results of repeated dose toxicity studies on NR that are relevant for deriving the NOAEL
Reference
Species, strain,
n/sex
Study duration
Guideline
GLP
Test
substance
Dose levels
(mg/kg bw)
Dose
mg/kg bw
Lowest dose with statistically significant effect, considered as substance related,
affected sex
% change if relevant for the decision on a NOAEL
Study No. SN17-940
(Unpublished)
(Thorsrud, 2018)
Dog, Beagle, 4m/4f
28 days
similar to OECD 408
GLP
NF
0, 100, 300,
500/1,000
100 m: prothrombin time ↓ (9%, not clearly dose related)
300 m: glucose ↑ (22%, not clearly dose related)
NOAEL
500/1,000 Salivation after dosing, abdominal contractions, diarrhoea, vomiting, bw ↓
m: sodium ↓, potassium ↓, eosinophils ↓, absolute and relative testes weights ↓ (not significant),
abs and relative thyroid weights ↓ (not significant)
f: AST ↑, phosphate ↓, fibrin ↓, rel. ovary weight ↑
Study No. S14022
(Unpublished) (Bhoite
et al., 2015)
Rat,
Sprague–Dawley,
10m/10f
90 days
OECD 408
GLP
NF
0,300, 1,000,
3,000
300 m: bw ↓ (8%), feed consumption ↓ (sometimes)
NOAEL
1,000 m: bw ↓ (9%), feed consumption ↓ (sometimes), leucocytes ↑
f: AST ↑, ALP ↑
m + f: neutrophils ↑, ALT ↑, triglycerides ↑, rel. liver weight ↑, rel. kidney weight ↑
3,000 m: bw ↓ (17%), feed consumption ↓ (9-14%), ALP ↑, bile acids ↑, abs liver weight ↑, abs and
rel. testes weight ↓, abs and rel. epididymis weight ↓, chronic progressive nephropathy, tubular
degeneration/atrophy of testes, reduced luminal sperm in epididymis and cellular debris
f: feed consumption ↓ (sometimes), leucocytes ↑, monocytes ↑, GGT ↑, rel. ovary weight ↑,
hypertrophy of corpora lutea
m + f: hepatocellular hypertrophy and necrosis, thyroid follicular cell hypertrophy, hypertrophy
of cortical zona glomerulosa in adrenals
Abs: absolute; ALP: alkaline phosphatase; AST: aspartate aminotransferase; bw: body weight; f: females; GLP: Good Laboratory Practice; GGT: gamma-glutamyltransferase; m: males; NOAEL: no
observed adverse effect level; OECD: Organisation for Economic Co-operation and Development; rel: relative.
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3.10.3. Reproductive and developmental toxicity
3.10.3.1. One generation reproduction toxicity study in rats
In a one-generation reproduction toxicity study (Study No. G10959, unpublished, GLP, OECD TG
415 (Ganiger, 2016)), the reproductive performance of male and female Sprague–Dawley rats and
potential developmental toxic effects of the NF were investigated. Four groups of animals (25/sex per
group) where administered diets (ad libitum) containing different concentrations of the NF (0, 3,000,
6,000 and 12,000 mg/kg feed, respectively, corresponding to 169, 334, and 675 mg/kg bw per day in
male rats and 273, 543, and 1,088 mg/kg bw per day in female rats) before mating, during pregnancy
and through weaning. The evaluation included clinical signs, body weight and food consumption. The
number, weight, survival and mortality of pups were recorded during the lactation period. Animals
were subjected to necropsy and histopathological examination of the male and female reproductive
organs was carried out.
At 12,000 mg/kg feed, lower body weight was observed only in males from treatment day 43 to
92, with reductions of 4.6–6.5%, when compared to the control group. Food consumption in the male
group receiving 12,000 mg/kg feed was significantly reduced at two time points. Due to the weak
effect, the finding on body weight was not considered as adverse by the authors of the study. The
Panel agrees with this view.
Other endpoints including precoital time, gestation length, fertility parameters, pathological and
histopathological examinations of reproductive organs of adult rats, survival and abnormalities in life
and death were not affected.
Based on the above results, it is concluded that the NOAEL for fertility and reproductive
performance is 12,000 mg/kg feed (675 mg/kg bw per day in males and 1,088 mg/kg bw per day in
females) under the testing conditions and doses employed.
The Panel notes that slight changes in body weight in male rats were consistent with the findings in
the repeated dose toxicity studies and support the NOAEL of 300 mg/kg bw per day.
3.10.3.2. Developmental toxicity study in rats
In an embryo-fetal developmental toxicity study (Study No. G10957, unpublished, GLP, OECD TG
414; (Geetha Rao, 2016)), the NF was administered to four groups of pregnant Sprague–Dawley rats
(24/group) at dose levels of 0, 325, 750 and 1,500 mg/kg bw per day by gavage, from gestation day
5 to 19. The evaluation included clinical signs, mortality, morbidity, body weight and food
consumption. After caesarean section dams were examined for gross pathological changes. Fetuses
were examined for sex, weight and external, visceral and skeletal malformations.
At doses of, respectively, 750 and 1,500 mg/kg bw of the NF, lower maternal feed consumption
(respectively, 6%, 12%), maternal body weight (4%, 8%), maternal body weight gain (11%,
28%), and maternal corrected body weight gain9 (55%, 107%) during gestation, were observed
as compared to the control group. Gravid uterine weights were reduced by 13% at 1,500 mg/kg bw
per day. Late resorptions were dose-relatedly increased (0.05, 0.29, 0.48, 0.52%), statistically
significant at 1,500 mg/kg bw. The mean fetal weight was significantly reduced by 6% and 17% at
750 and 1,500 mg/kg per day, respectively. The Panel considers these findings secondary to maternal
toxicity.
At the 1,500 mg/kg per day dose, there was a significant increase in the incidence of fetal
anasarca. In addition, there were incidences of two small fetuses, an incidence of a fetus with
moderate flexed right forelimb and one fetus with a thread-like tail.
Fetal skeletal examination revealed dose-dependent increases in delayed, incomplete or poor
ossification that were statistically significant in the high dose for some sternebrae, some cervical and
thoracic vertebrae, pubis and in some phalanges of fore and hindlimbs. In addition, as minor anomaly,
there was an increase of extra, accessory, and rudimentary rib No.14 (10.32; 10.26; 16.47 and
30.72% of the fetuses, which was statistically significant at 1,500 mg/kg bw), and a hypoplastic
sternum No. 2 (0, 1.28, 4.12, 24.84% of the fetuses, statistically significant at 750 and 1,500 mg/kg
bw). The incidence of the finding at 750 mg/kg bw was within the historical control range and
therefore not considered as adverse by the investigating laboratory. The Panel notes that these
skeletal findings are often associated with general toxicity/reduced body weight gain of the dams.
9 Corrected body weight gain = (maternal weight change between day 5 and day 20) – gravid uterus weight.
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Based on the above findings, it is concluded that the NOAEL for maternal toxicity is 325 mg/kg bw
per day. The NOAEL for embryo/fetotoxicity is also 325 mg/kg bw per day; effects observed at
750 mg/kg bw per day are considered secondary to maternal toxicity.
3.10.3.3. Other studies
In a test performed on human embryonic kidney (HEK) 293 cells transfected with a human ether-
ago-go-related gene (hERG) (Study No. 20151223, unpublished), the NF did not affect the functioning
of the human potassium channel as no inhibition of the hERG tail current density was observed.
3.10.4. Human data
The applicant provided one single dose pharmacokinetic study (Wilson, 2015; Trammell et al.,
2016a) and four clinical trials (Airhart et al., 2017; Martens, 2017; Dollerup et al., 2018; Martens et al.,
2018; Schacter, 2018; Conze et al., 2019) in which safety-related parameters following the
consumption of the NF were addressed (Table 6).
The Panel notes that in these studies on healthy, adult human subjects, with doses of the NF from
100 mg for one day up to 2,000 mg/day for 12 weeks, changes in haematology and clinical chemistry
remained within reference ranges and that no dose-dependent adverse effects in the safety parameter
examined were observed.
Studies suggest that high NAM intake, that undergoes methylation-mediated degradation, could
affect the methyl group pool balance (Sun et al., 2012, 2017; Li et al., 2013; Tian et al., 2013, 2014).
However, the Panel considers that these studies on NAM do not allow firm conclusions on potential
adverse effects.
The applicant conducted a post hoc analysis of the blood samples collected in the 8-week
supplementation study by (Schacter, 2018; Conze et al., 2019) using sodium citrate-treated plasma
collected before and after 8 weeks of NF ingestion up to 1,000 mg/day. Plasma homocysteine
concentrations were quantified by liquid chromatography coupled with tandem mass spectrometry. The
ingestion of up to 1,000 mg NF/day had no effect on plasma homocysteine concentrations.
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Table 6: Overview table of human studies
Reference
Study
design
Study
population
Duration of
Study
Doses
Safety-related
parameters
investigated
Summary of Results
Schacter
(2018) and
Conze et al.
(2019)
Randomised,
double-blind,
placebo-
controlled
parallel study
140 healthy men
and women
(30/dose group)
Age:
40–60 years
BMI:
25.0–30.1 kg/m2
2-week run-in
and 8-week
supplementation
period
100 mg NF/day
300 mg NF/day
1,000 mg
NF/day Placebo
Anthropometric
measures and vital
signs, haematology
and clinical chemistry
(blood lipids, CBC, Na,
K, Cl, HbA1c,
creatinine, BUN, AST,
ALT, GGT, bilirubin),
and incidence of
adverse events (AE)
AEs classified as possibly related to the treatment
100 mg NR (2 AEs): leg pain, high blood pressure; 300 mg
NR (2 AEs): nausea, leg pain; 1,000 mg NR (3 AEs): sore
back, muscle soreness, nausea; placebo (4 AEs): rash, raised
liver function tests, nausea, upset stomach.
Haematology and clinical chemistry
Significant between-group difference in participants’ WBC
count between the 300 mg NR and placebo at week 8
(p = 0.048) within clinical reference ranges
Significant between-group difference in the change in RBC
distribution width from screening to week 8 between the
1,000 mg NR group and placebo (p = 0.038) within clinical
reference ranges
Significant between-group difference eosinophil count
between the 1,000 mg NR group and 100 mg NR group,
300 mg NR group, and placebo group at week 4 (p = 0.037,
p = 0.009 and p = 0.047, respectively) within clinical
reference ranges
Liver function
Significant between-group difference in the change in ALT
from baseline to week 1 between the 1,000 mg NR group and
the 100 mg NR group (p = 0.013) and placebo group
(p = 0.033) and in the change in ALT from baseline to week 2
between the 1,000 mg NR group and 100 mg NR group
(p = 0.025) and placebo group (p < 0.001) within clinical
reference ranges
Significant between-group difference in AST between the
1,000 mg NR group and placebo (p = 0.019) at week 2 within
clinical reference ranges
Significant between-group difference in the change in AST
from baseline to week 2 between the 1,000 mg NR group and
300 mg NR group (p = 0.040) within clinical reference ranges
Vital signs and anthropometric measures
No significant between-group differences
www.efsa.europa.eu/efsajournal 23 EFSA Journal 2019;17(8):5775
Nicotinamide riboside chloride
Reference
Study
design
Study
population
Duration of
Study
Doses
Safety-related
parameters
investigated
Summary of Results
Wilson (2015) Single centre,
three arm,
randomised,
double-blind
cross-over
study
16 healthy men
or women
Age:
30–55 years
BMI:
18.5–29.9 kg/m2
Each individual
receives each
dose on
separate study
days with a
7-day wash-out
period between
study days
100 mg NF
300 mg NF
1,000 mg NF
Vital signs,
haematology and
clinical chemistry
(fasting glucose, eGFR,
CBC, Na, K, Cl,
creatinine, urate, AST,
ALT, GGT, bilirubin),
and monitoring of AEs
AEs classified as possibly related to the treatment
100 mg NR (1 AE): decrease in haemoglobin (participant
withdrawn); 300 mg NR (1 AE): decrease in WBC count
(participant withdrawn)
Haematology and clinical chemistry
Significant between-group difference in participants’
neutrophils count between the 300 mg NR group and
1,000 mg NR group (p = 0.026) within clinical reference
ranges
Vital signs
No significant between-group differences
Martens
(2017) and
Martens et al.
(2018)
Randomised,
placebo-
controlled,
double blind,
crossover
study
30 healthy men
and women
Age:
55–79 years
BMI: < 40 kg/m2
Each group
received placebo
or NR for
6 weeks
(29/day)
followed by
opposite
treatment for
6 weeks. No
washout period
was included;
carryover not
expected
500 mg NF per
day
Placebo
AEs and self-reported
side effects,
anthropometric
measures,
haematology and
clinical chemistry
(CBC, blood lipids,
total protein, albumin,
AST, ALT, creatinine,
BUN, eGFR, Ca,
glucose, Na, K, Cl,
CO2)
AEs classified as possibly related to the treatment
NR group (3 AEs): nausea, muscle cramps, and increased
bruising
Haematology and clinical chemistry
Significant between-group differences in mean platelet
volume and relative (%) eosinophil and basophil
composition after 6 weeks, within the normal reference
range
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Reference
Study
design
Study
population
Duration of
Study
Doses
Safety-related
parameters
investigated
Summary of Results
Dollerup et al.
(2018)
Randomised,
double-
blinded,
placebo
controlled,
parallel-group
study
40 healthy obese
(BMI > 30 kg/m2)
Caucasian males
Age: 40–70 years
Sedentary
(< 30 min
exercise per day),
non-smokers, and
no prescribed
medicine
Each group
received
treatment or
placebo twice
daily for
12 weeks
1,000 mg NF, 2
times per day
Placebo
Anthropometric
measures,
haematology and
clinical chemistry
(creatinine, Na, K,
urea nitrogen,
albumin, ALT, AST,
bilirubin, haemoglobin,
WBC count and
platelets, fasting
glucose, fasting
insulin, HbA1c, blood
lipids) and monitoring
of AEs
AEs classified as possibly related to the treatment
NR group (4 AEs): pruritus, excessive sweating, bloating, and
transient changes in stool
Placebo group (2 AEs)
Haematology and clinical chemistry
Three participants from the placebo group displayed mild
thrombocytosis (< 700 9 109/L)
Significant increase in plasma triglycerides from a
pretreatment mean of 1.5 mmol/L to a post-treatment mean
of 1.8 mmol/L in the NR group (within-group p = 0.01), within
the normal reference
No significant between-group differences reported
Airhart et al.
(2017)
Open-label,
non-
randomised
study
8 healthy men
and women, ages
21–50
10 days 250 mg NF was
orally
administered on
days 1 and 2,
then up-titrated
to peak dose of
1,000 mg twice
daily on days 7
and 8. On the
morning of day
9, subjects
completed a
24-h
pharmacokinetic
study after
receiving
1,000 mg of the
NF at t = 0
Anthropometric
measures,
haematology and
clinical chemistry
(CBC, Na, Cl, glucose,
BUN, creatinine,
creatine kinase, AST,
ALT, uric acid, lactate
dehydrogenase) and
self-reported AEs
No AEs or side effects were reported.
Haematology and clinical chemistry (between baseline and
day 9)
Serum K decreased by an average of 0.4 mEq/L (p = 0.015),
within normal range
Decrease in haematocrit (2%, p = 0.005), haemoglobin
(0.4 g/dL, p = 0.04), and platelet count (20,000/lL,
p = 0.03)
AE: adverse event; ALT: alanine transaminase; AST: aspartate transaminase; BMI: body mass index; BUN: blood urea nitrogen; Ca: calcium; CBC: complete blood count; Cl: chloride; eGFR:
estimated glomerular filtration rate; GGT: gamma-glutamyltransferase; HbA1c: haemoglobin A1c; K: potassium; Na: sodium; NR: nicotinamide riboside chloride; RBC: red blood cell; WBC: white
blood cell.
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3.11. Allergenicity
The NF is a synthetic product containing > 90 % nicotinamide riboside chloride. Potential process
impurities have been well characterised. Since the NF does not contain any protein, the risk of
allergenicity is low.
4. Discussion
The NF, nicotinamide riboside chloride, is a synthetic form of nicotinamide riboside, proposed to be
used in food supplements at levels up to 300 mg/day. The NF is intended for use by the healthy adult
population, including pregnant and lactating women.
Information provided on the production process, composition, specifications, batch-to-batch
variability and stability of the NF is sufficient and does not raise concerns about the safety of the NF.
Considering the outcomes of the bacterial reverse mutagenicity test, the in vivo mammalian
erythrocyte micronucleus test and the in vitro mammalian chromosome aberration test conducted with
the NF, as well as its nature, the Panel considers that there are no concerns regarding genotoxicity.
From the ADME data available in mice, rats, dogs, and humans, the Panel notes that the NF is likely
to be absorbed mainly as NAM following hydrolysis in the gut. If a fraction of the NF were absorbed
intact, it would be expected to be rapidly metabolised to NAM in the blood. Animal and human data
indicate that, upon absorption, the NF contributes to the NAM body pool, i.e. acts as a precursor of
NAD+ in cells and is primarily metabolised in the liver to 1-MN through methylation and subsequently
to 2-PY, and 4-PY, following oxidation. These metabolites are then excreted in the urine.
The Panel derives a NOAEL of 300 mg/kg bw per day from the repeated dose toxicity studies with
rats and dogs conducted with the NF. The Panel notes that in the 90-day study in rats, equimolar
doses of NAM and the NF (1,260 mg/kg bw per day of NAM vs 3,000 mg/kg bw per day nicotinamide
riboside chloride) caused the same effects. Reproductive and developmental toxicity studies in rats
with the NF were also provided, which indicate a NOAEL for fertility and reproductive performance of
675 mg/kg bw per day in males and 1,088 mg/kg bw per day in females and a NOAEL for maternal
and embryo/fetotoxicity of 325 mg/kg bw per day. The embryo/fetotoxicity findings observed at a
dose of 750 mg/kg bw per day are considered secondary to maternal toxicity.
The Panel considers that available human studies on the NF, which were conducted in healthy adult
subjects with dosages from 100 mg for one day up to 2,000 mg/day for up to 12 weeks, do not raise
safety concerns. The safety parameters addressed in these studies were vital signs, haematology and
clinical chemistry.
The proposed maximum use level of 300 mg nicotinamide riboside chloride per day corresponds to
an intake of NAM of up to 126 mg/day. This intake is sixfold lower than the current UL for NAM of
900 mg/day for adults (excluding pregnant and lactating women) in the EU (SCF, 2002).
The margin of exposure (MoE) between the proposed maximum use level of 300 mg/day (i.e.
4.3 mg/kg bw in a 70-kg adult) and the NOAEL of 300 mg/kg bw per day derived from animal data is
70. In the light of the human data available on nicotinamide riboside chloride and NAM, the
Panel considers that this MoE is sufficient for the adult population, excluding pregnant and lactating
women.
The MoE between the proposed maximum use level of 300 mg/day (i.e. 4.3 mg/kg bw in a 70-kg
adult) and the NOAEL of 325 mg/kg bw per day for maternal and embryo/fetotoxicity derived from the
rat study, is 76. In the absence of data which could justify a MoE lower than 100 for pregnant and
lactating women, the Panel concludes that an intake of 230 mg/day of the NF (rounded to the nearest
ten) is safe for these population groups.
5. Conclusions
The Panel concludes that the NF, nicotinamide riboside chloride, is safe under the proposed uses
and use levels, i.e. up to 300 mg/day, for the healthy adult population, excluding pregnant and
lactating women. The Panel concludes that an intake of the NF up to 230 mg/day is safe for pregnant
and lactating women.
The Panel also concludes that nicotinamide riboside chloride is a source from which NAM, which is
a form of niacin, is bioavailable.
The Panel could not have reached the conclusion on the safety of the NF under the proposed
conditions of use without the following data claimed as proprietary by the applicant: an in vitro study
evaluating the metabolism of nicotinamide riboside in blood (Study No. 160312); an oral 7-day dose
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range finding toxicity study in juvenile dogs (study No. SN17-921); a 28-day repeated-dose oral
toxicity study in juvenile dogs (Study No. SN17-940); a 90-day repeated-dose oral toxicity study in
Sprague–Dawley rats (Study No. S14022); a reproductive toxicity study (Study No. G10959) and a
developmental toxicity study (Study No. G10957) in rats.
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on synthetic form of nicotinamide riboside. Ref. Ares(2018)
5155905, dated 8 October 2018.
2) On 08 October 2018, a valid application on the Use of NIAGEN® for General Use as a Novel
Food Ingredient in Supplements per Commission Implementing Regulation (EU) 2017/2469,
which was submitted by ChromaDex Inc., was made available to EFSA by the European
Commission through the Commission e-submission portal (NF 2018/0233) and the scientific
evaluation procedure was initiated.
3) On 27 February 2019, EFSA requested the applicant to provide additional information to
accompany the application and the scientific evaluation was suspended.
4) On 20 March 2019, additional information was provided by the applicant through the
Commission e-submission portal and the scientific evaluation was restarted.
5) During its meeting on 04 July 2019, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of nicotinamide riboside chloride as a NF pursuant to
Regulation (EU) 2015/2283.
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Abbreviations
1-MN 1-methylnicotinamide
2-PY N-methyl-2-pyridone-carboxamide
4-PY N-methyl-4-pyridone-carboxamide
ADME asorption, distribution, metabolism and excretion
ADPR adenine diphosphate ribose
AE adverse events
ALP alkaline phosphatase
ALT alanine transaminase
AOAC Association of Analytical Communities
AR average requirement
AST aspartate transaminase
AUC area under the curve
BMI body mass index
BUN blood urea nitrogen
bw body weight
CAS Chemical Abstracts Service
CBC complete blood count
CFU colony forming units
Cmax maximum concentration
DRV dietary reference values
EC Enzyme Commission
eGFR estimated glomerular filtration rate
ESI-MS electrospray ionisation mass spectrometry
GC-FID gas chromatography coupled with a flame ionisation detector
GGT gamma-glutamyltransferase
GLP Good Laboratory Practice
GMP Good Manufacturing Practice
GRAS generally recognized as safe
HACCP Hazard Analysis Critical Control Points
HbA1c haemoglobin A1c
HDPE high-density polyethylene
hERG human ether-ago-go-related gene
HPBL human peripheral blood lymphocyte
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HPLC-UV high-performance liquid chromatography-ultraviolet spectroscopy
HPLC UV-Vis high-performance liquid chromatography coupled with ultraviolet/visible spectroscopy
ICP-MS inductively coupled plasma mass spectrometry
ITT intention-to-threat
IUPAC International Union of Pure and Applied Chemistry
LDPE low-density polyethylene
LNHPD Licensed Natural Health Products Database
LOQ limit of quantitation
MoE margin of exposure
NA nicotinic acid
NaAD nicotinic acid adenine dinucleotide
NAD+ nicotinamide adenine dinucleotide
NAM nicotinamide
NaR nicotinic acid ribose
NDA EFSA Panel on Nutrition, Novel foods and Food Allergens
NDI new dietary ingredient
NE niacin equivalent
NF novel food
NMN nicotinamide mononucleotide
NMR nuclear magnetic resonance
NOAEL no observed adverse effect level
NR nicotinamide riboside chloride
Nrk nicotinamide riboside kinase
OECD Organisation for Economic Co-operation and Development
P/E polychromatic erythrocyte/total erythrocyte
PAL physical activity level
PP per-protocol
PRI population reference intake
RBC red blood cell
RH relative humidity
TK toxicokinetic
Tmax time at which the Cmax is observed
UF uncertainty factor
UL tolerable upper intake level
UMP uridine monophosphate
USP United States Pharmacopeia
WBC white blood cell
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